Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 1

Status

Completed 4

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 4Other solid neoplasm 3Other hematologic neoplasm 2Thoracic 1Sarcoma 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1CNS 1Breast 1

Conditions

Neoplasms 2Neoplasm Metastasis 1Carcinoma 1

Interventions

pembrolizumab 46Paclitaxel 46Gemcitabine 41Carboplatin 37Docetaxel 35Bevacizumab 27Cisplatin 25Irinotecan 22Nivolumab 20Fluorouracil 20Erlotinib Hydrochloride 18Pemetrexed 17Capecitabine 17Sorafenib 16Magnetic Resonance Spectroscopy 16Cetuximab 16Afatinib 16Leucovorin 15regorafenib 14olaparib 13Specimen Handling 13Oxaliplatin 13trametinib 12Biopsy 12130-nm albumin-bound paclitaxel 11eribulin 10atezolizumab 10epothilone B 9Radiotherapy 9Midazolam 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Tablets × Tumor-Agnostic × Clear all
NCT01173913 2019-01-10

Weekly Administration of (bi-)Daily Oral Docetaxel in Combination With Ritonavir

The Netherlands Cancer Institute

Phase 1 Completed
57 enrolled
Tumor-Agnostic

Neoplasms

NCT02536391 2016-11-02

Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy Subjects

Genentech, Inc.

Phase 1 Completed
18 enrolled
Tumor-Agnostic

Neoplasms

NCT00941863 2016-03-22

Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)

Bayer

Phase 1 Completed
158 enrolled 17 charts
Tumor-Agnostic

Carcinoma

NCT00667485 2014-01-17

Rapamycin Plus Bevacizumab in Advanced Cancers

University of Chicago

Phase 1 Completed
28 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡